Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study

Table 1 Demographic and clinical characteristics of patients at baseline

Characteristic	Baseline values (n = 32)
Sex
Male	17 (53.1%)
Female	15 (46.9%)
ECOG performance status
0	17 (53.1%)
1	15 (46.9%)
Mean age (range) - years	65.4 (20–85)
M-stage
M1a	4 (12.5%)
M1b	4 (12.5%)
M1c	24 (75.0%)
Visceral metastases	28 (87.5%)
Non visceral metastases	4 (12.5%)
LDH level
</=Upper limit of the normal range	18 (56.3%)
> Upper limit of the normal range	14 (43.8%)
Number of previous therapies
1	17 (53.1%)
2	7 (21.9%)
3	4 (12.5%)
≥4	4 (12.5%)
Previous anticancer treatment
Chemotherapy^*	29 (90.6%)
Immunotherapy^**	12 (37.5%)
Other anticancer therapy^***	8 (25.0%)

Data are number (%) or mean. ^*Carboplatin, Cisplatin, DTIC, Fotemustine, Gemcitabine, Melphalan, Paclitaxel, Treosulfan, Vindesine, ^**IFN, Ipilimumab, Thymosin, ^***CNTO, Genasense, Imatinib, Sorafenib, STA-4783-08.